ARTICLE | Finance
Next inflection points come into focus for Gilead, Moderna following Friday’s big gains
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 17, 2020 10:24 PM UTC
Buoyed by optimism for their COVID-19 products, Gilead and Moderna collectively added almost $12 billion in value Friday.
The next inflection points for the company’s stocks are linked to a clinical readout this month for Gilead’s antiviral remdesivir, and a Phase II trial start this quarter for Moderna (see “Timeline of Upcoming COVID-19 Trial Readouts”)...